Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.34 |
| ▸ | KRAS | P01116 | 3/20 | 0.34 |
| ▸ | BTK | Q06187 | 4/20 | 0.33 |
| ▸ | CCNK | O75909 | 2/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046493 | 0.83 | SOS1 (0.41) | JAK3KRASBTKEGFR | |
| SCHEMBL20046111 | 0.82 | MAP3K5 (0.36) | KRASBTKEGFRKDM5A | |
| SCHEMBL20046512 | 0.82 | KDM5A (0.35) | KRASBTKEGFRKDM5A | |
| SCHEMBL20045939 | 0.81 | BTK (0.36) | KRASBTKFGFR2 | |
| SCHEMBL20045483 | 0.81 | MAPK1 (0.41) | JAK3KRASEGFR | |
| SCHEMBL20045461 | 0.81 | PIK3CD (0.36) | KRASEGFR | |
| SCHEMBL20046108 | 0.81 | KRAS (0.37) | KRASCCNKCDK12 | |
| SCHEMBL20045937 | 0.80 | USP30 (0.41) | KRASBTKEGFR | |
| SCHEMBL20046107 | 0.80 | TDP2 (0.38) | JAK3KRASBTKEGFRKDM5A | |
| SCHEMBL20045454 | 0.79 | KRAS (0.51) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | JAK3 3141/4885KRAS 1/4885BTK 758/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | JAK3 2953/4885KRAS 1/4885BTK 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.